China – Future Obesity Treatment Market

1 Min Read
Chinese people with a body mass index (BMI) of 24-25.9 had the lowest risk of death, according to a study published in CMAJ (Canadian Medical Association Journal). Obesity has increased significantly across the globe and the World Health Organization (WHO) estimates that about 2.3 billion adults will be overweight and more than 700 million will be obese by 2015. Overweight and obesity are associated with increased risks of heart disease, diabetes, cancer and other chronic diseases…
Among numerous downsides of rapid economic development (increased polution, inflation) are the ills characteristic of affluent Western economies and that includes a high and growing prevalence of obesity. China therefore holds the potential for significant future demand in obesity treatments (see also http://www.mediligence.com/rpt/rpt-s835.htm).
Share This Article
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version